Werewolf Therapeutics, Inc. ( (HOWL) ) has released its Q1 earnings. Here is a breakdown of the information Werewolf Therapeutics, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company focused on developing therapeutics to stimulate the immune system for cancer treatment, operating within the biotechnology sector. In its latest earnings report for the quarter ending March 31, 2025, Werewolf Therapeutics highlighted a net loss of $18.1 million, compared to a $16.2 million loss in the same period last year, with no revenue generated from product sales. Key financial metrics revealed a decrease in cash and cash equivalents to $92 million from $111 million at the end of 2024, while operating expenses remained stable at approximately $18 million. The company continues to invest heavily in research and development, accounting for the majority of its expenditures. Looking ahead, Werewolf Therapeutics remains focused on advancing its pipeline, particularly its INDUKINE molecules, and anticipates the need for additional funding to support ongoing and future clinical activities.